<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990573</url>
  </required_header>
  <id_info>
    <org_study_id>201302099</org_study_id>
    <nct_id>NCT01990573</nct_id>
  </id_info>
  <brief_title>Methadone in Pediatric Anesthesiology II</brief_title>
  <acronym>MEPAII</acronym>
  <official_title>Methadone in Pediatric Anesthesia II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three arm randomized controlled trial to evaluate the efficacy of a single dose of
      intraoperative methadone in reducing post-operative pain and opioid consumption in
      adolescents undergoing posterior spinal fusion. Our secondary goal is to determine the
      pharmacokinetics of IV methadone in children (0.3 and 0.4 mg/kg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, controlled, modified dose-escalation design. Patients receive standard monitoring
      for anesthesia and postoperative care. Surgical and anesthesia (except for opioid use) care
      are not altered for study purposes. All patients are induced by propofol and muscle
      relaxants. In the first cohort (n=30 evaluable), subjects are randomized 1:2 to either
      control (standard intraop opioid at anesthesiologists' discretion) or methadone HCl (0.4
      mg/kg ideal body weight, IBW). In the second cohort (n=30 evaluable), subjects are randomized
      1:2 to either control (standard intraop opioid) or methadone HCl (0.3 mg/kg ideal body
      weight, IBW). Subjects in the study groups will receive methadone (IV bolus, after induction
      of anesthesia) as their primary intraoperative opioid, rather than leaving the choice of
      intraoperative opioid to the anesthesiologist. Intraoperative breakthrough pain will be
      treated at the discretion of the anesthesiologist with fentanyl. In the control groups,
      intraoperative opioid administration will be left at the discretion of the anesthesia
      providers. Patient controlled analgesia as prescribed by the clinical team, using
      hydromorphone or morphine, will be used to treat postoperative pain relief.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2013</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Opioid Consumption (Morphine Equivalent)</measure>
    <time_frame>6 days</time_frame>
    <description>Measure of overall morphine consumption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>6 days</time_frame>
    <description>Assessments are made in the postoperative period by a trained member of the research team blinded to intraoperative use of methadone. These will be conducted on each post-operative day until discharge or post op day 6, whichever comes first. Pain intensity is assessed using the numeric pain score (0-10) scale employed by the inpatient nursing staff and previously validated .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of R and S Methadone</measure>
    <time_frame>96 hours</time_frame>
    <description>Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>methadone HCl 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg/kg IV methadone HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methadone HCl 0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4mg/kg IV methadon HCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control no methadone, standard of care opioids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3mg/kg IV methadone HCl</intervention_name>
    <description>Group I will receive 0.3mg/kg IV methadone HCl</description>
    <arm_group_label>methadone HCl 0.3 mg/kg</arm_group_label>
    <other_name>methadone HCl, dolophine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4mg/kg IV methadon HCl</intervention_name>
    <description>Group II will receive 0.4mg/kg IV methadone HCl.</description>
    <arm_group_label>methadone HCl 0.4 mg/kg</arm_group_label>
    <other_name>methadone HCl, dolophine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control no methadone</intervention_name>
    <description>The control group will not receive methadone.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.

          -  Age 11-18 years

          -  Undergoing general anesthesia and idiopathic posterior spinal surgery with anticipated
             postop inpatient stay of &gt; 3 days

          -  Signed, written, informed consent from legal guardians and assent from patient

        Exclusion Criteria.

          -  History of or known liver or kidney disease.

          -  Females who are pregnant or nursing.

          -  Children with developmental delay

          -  Children undergoing surgery for scoliosis of musculoskeletal origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anshuman Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <results_first_submitted>September 9, 2019</results_first_submitted>
  <results_first_submitted_qc>January 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2020</results_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal surgery</keyword>
  <keyword>Methadone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01990573/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01990573/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>53 signed consents however, 2 participants withdrew prior to randomization:
1 per family request
1 unable to complete</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Methadone HCl 0.3 mg/kg</title>
          <description>0.3mg/kg IV methadone HCl
0.3mg/kg IV methadone HCl: Group I will receive 0.3mg/kg IV methadone HCl</description>
        </group>
        <group group_id="P2">
          <title>Methadone HCl 0.4 mg/kg</title>
          <description>0.4mg/kg IV methadon HCl
0.4mg/kg IV methadon HCl: Group II will receive 0.4mg/kg IV methadone HCl.</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>control no methadone, standard of care opioids.
control no methadone: The control group will not receive methadone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methadone 0.3 mg/kg</title>
          <description>0.3mg/kg IV methadone
0.3mg/kg IV methadone : Group I will receive 0.3mg/kg IV methadone</description>
        </group>
        <group group_id="B2">
          <title>Methadone 0.4 mg/kg</title>
          <description>0.4mg/kg IV methadone
0.4mg/kg IV methadone: Group II will receive 0.4mg/kg IV methadone .</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>control no methadone, standard of care opioids.
control no methadone: The control group will not receive methadone.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.7" spread="1.5"/>
                    <measurement group_id="B2" value="14.8" spread="1.9"/>
                    <measurement group_id="B3" value="14.5" spread="1.9"/>
                    <measurement group_id="B4" value="14.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists (ASA) Physical Satus</title>
          <description>The purpose of the system is to assess and communicate a patient’s pre-anesthesia medical co-morbidities. The classification system alone does not predict the perioperative risks, but used with other factors (eg, type of surgery, frailty, level of deconditioning), it can be helpful in predicting perioperative risks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ASA 1 -A normal healthy patient</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA 2 - A patient with mild systemic disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative pain score</title>
          <description>Numeric Pain Score was used to measure patient reported pain. The scale, previously validated, measures pain from 0 to 10, zero being no pain and 10 being the highest imaginable pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="2.1"/>
                    <measurement group_id="B2" value=".6" spread="1.2"/>
                    <measurement group_id="B3" value="1.9" spread="3.1"/>
                    <measurement group_id="B4" value="1.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expected Post-operative Pain Score</title>
          <description>Numeric Pain Score was used to measure patient reported pain. The scale, previously validated, measures pain from 0 to 10, zero being no pain and 10 being the highest imaginable pain</description>
          <units>0-10 units on a Visual Analog scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="2.1"/>
                    <measurement group_id="B2" value="6.9" spread="2.0"/>
                    <measurement group_id="B3" value="7.5" spread="1.9"/>
                    <measurement group_id="B4" value="7.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2 scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="3.8"/>
                    <measurement group_id="B2" value="21.3" spread="2.4"/>
                    <measurement group_id="B3" value="22.4" spread="4.8"/>
                    <measurement group_id="B4" value="21.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Opioid Consumption (Morphine Equivalent)</title>
        <description>Measure of overall morphine consumption</description>
        <time_frame>6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone HCl 0.3 mg/kg</title>
            <description>0.3mg/kg IV methadone HCl
0.3mg/kg IV methadone HCl: Group I will receive 0.3mg/kg IV methadone HCl</description>
          </group>
          <group group_id="O2">
            <title>Methadone HCl 0.4 mg/kg</title>
            <description>0.4mg/kg IV methadon HCl
0.4mg/kg IV methadon HCl: Group II will receive 0.4mg/kg IV methadone HCl.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>control no methadone, standard of care opioids.
control no methadone: The control group will not receive methadone.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Consumption (Morphine Equivalent)</title>
          <description>Measure of overall morphine consumption</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread=".84"/>
                    <measurement group_id="O2" value="2.37" spread=".86"/>
                    <measurement group_id="O3" value="3.28" spread=".93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <p_value>.002</p_value>
            <method>ANOVA</method>
            <param_type>F statistic</param_type>
            <param_value>.002</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores</title>
        <description>Assessments are made in the postoperative period by a trained member of the research team blinded to intraoperative use of methadone. These will be conducted on each post-operative day until discharge or post op day 6, whichever comes first. Pain intensity is assessed using the numeric pain score (0-10) scale employed by the inpatient nursing staff and previously validated .</description>
        <time_frame>6 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methadone HCl 0.3 mg/kg</title>
            <description>0.3mg/kg IV methadone HCl
0.3mg/kg IV methadone HCl: Group I will receive 0.3mg/kg IV methadone HCl</description>
          </group>
          <group group_id="O2">
            <title>Methadone HCl 0.4 mg/kg</title>
            <description>0.4mg/kg IV methadon HCl
0.4mg/kg IV methadon HCl: Group II will receive 0.4mg/kg IV methadone HCl.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>control no methadone, standard of care opioids.
control no methadone: The control group will not receive methadone.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>Assessments are made in the postoperative period by a trained member of the research team blinded to intraoperative use of methadone. These will be conducted on each post-operative day until discharge or post op day 6, whichever comes first. Pain intensity is assessed using the numeric pain score (0-10) scale employed by the inpatient nursing staff and previously validated .</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.4"/>
                    <measurement group_id="O2" value="4.6" spread="2.9"/>
                    <measurement group_id="O3" value="4.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <p_value>.962</p_value>
            <method>ANOVA</method>
            <param_type>F statistic</param_type>
            <param_value>.962</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of R and S Methadone</title>
        <description>Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.</description>
        <time_frame>96 hours</time_frame>
        <population>Methadone clearance was only measured in the two groups that received methadone</population>
        <group_list>
          <group group_id="O1">
            <title>Methadone HCl 0.3 mg/kg</title>
            <description>0.3mg/kg IV methadone HCl
0.3mg/kg IV methadone HCl: Group I will receive 0.3mg/kg IV methadone HCl</description>
          </group>
          <group group_id="O2">
            <title>Methadone HCl 0.4 mg/kg</title>
            <description>0.4mg/kg IV methadon HCl
0.4mg/kg IV methadon HCl: Group II will receive 0.4mg/kg IV methadone HCl.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of R and S Methadone</title>
          <description>Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.</description>
          <population>Methadone clearance was only measured in the two groups that received methadone</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>R- Methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" spread="37"/>
                    <measurement group_id="O2" value="175" spread="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S- Methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="43"/>
                    <measurement group_id="O2" value="226" spread="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 days post-preoperative.</time_frame>
      <desc>Patients were assessed each day, in the morning, for events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Methadone HCl 0.3 mg/kg</title>
          <description>0.3mg/kg IV methadone HCl
0.3mg/kg IV methadone HCl: Group I will receive 0.3mg/kg IV methadone HCl</description>
        </group>
        <group group_id="E2">
          <title>Methadone HCl 0.4 mg/kg</title>
          <description>0.4mg/kg IV methadon HCl
0.4mg/kg IV methadon HCl: Group II will receive 0.4mg/kg IV methadone HCl.</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>control no methadone, standard of care opioids.
control no methadone: The control group will not receive methadone.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Delayed return of bowel sounds</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Depression</sub_title>
                <description>Respiratory Rate &lt;8/min or Saturations &lt;90% for more than 30 sec</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Excessive sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anshuman Sharma</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-457-3147</phone>
      <email>sharma.a@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

